Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
87
Recruiting, any sponsor type, condition "hepatitis B"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed843
87 trials
Showing 1 to 25, recently updated first.
AusperBio Therapeutics Inc.Industry
NCT07370207 · 84 participants (planned) · Start Mar 6, 2026 · Primary completion Dec 31, 2028
Drug: AHB-137 · For: Hepatitis B, Chronic
Sites: Fitzroy, Australia; Hong Kong, China; Musashino, Japan · 9 sites in all
- Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe RegionsRecruiting
AusperBio Therapeutics Inc.Industry
NCT07654283 · 70 participants (planned) · Start Sep 1, 2026 · Primary completion Nov 11, 2027
Drug: AHB-137 · For: Hepatitis B, Chronic
Sites: Redwood City, California; Baltimore, Maryland; New York, New York · 10 sites in all
Fujian Akeylink Biotechnology Co., Ltd.Industry
NCT07944482 · 24 participants (planned) · Start Jul 3, 2026 · Primary completion Dec 31, 2026
Drug: GST-HG141 · For: Chronic Hepatitis b
Sites: Suzhou, China
- A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.Pivotal-lookingRecruiting
Beijing Continent Pharmaceutical Co, Ltd.Industry
NCT07412236 · 1,208 participants (planned) · Start Mar 23, 2026 · Primary completion Dec 30, 2028
Drug: Hydronidone (270mg); Hydronidone (Placebo Group) · For: Liver Fibrosis; Liver Fibrosis in Chronic Hepatitis B
Sites: Shanghai, China
Jiyan LiuAcademic, hospital or other
NCT07051187 · 9 participants (planned) · Start Dec 1, 2026 · Primary completion Sep 1, 2027
Drug: WGc0201 · For: Chronic Hepatitis B Virus (Hbv)
Sites: Chengdu, China
- Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis BPivotal-lookingRecruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07606950 · 540 participants (planned) · Start Jul 17, 2026 · Primary completion Jun 2028
Drug: HRS-5635 Injection; Placebo · For: Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
Sites: Guangzhou, China
Jidong JiaAcademic, hospital or other
NCT04939441 · 100 participants (planned) · Start Apr 20, 2021 · Primary completion Dec 31, 2027
Drug: Tenofovir alafenamide · For: Chronic Hepatitis B
Sites: Beijing, China; Suzhou, China; Nanchang, China · 9 sites in all
- Study of BK1803 in Healthy InfantsPivotal-lookingRecruiting
Tanabe Pharma CorporationIndustry
NCT07793513 · 344 participants (planned) · Start Oct 21, 2026 · Primary completion Apr 2029
Drug: BK1803; GOBIK Aqueous Suspension Syringes and 1 more · For: Pertussis; Diphtheria; Tetanus and 3 more
Sites: Fukui-shi, Japan; Fukuoka, Japan; Isesaki, Japan · 33 sites in all
- Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib)Pivotal-lookingRecruiting
Serum Institute of India Pvt. Ltd.Industry
NCT07855172 · 186 participants (planned) · Start Nov 1, 2026 · Primary completion Oct 2027
Drug: Hexavalent (DTwP-HepB-rPV-Hib) Vaccine; HEXASIIL · For: Diptheria Immunization; Tetanus Immunization; Pertussis Immunization and 3 more
Sites: Dhaka, Bangladesh
- A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)Pivotal-lookingRecruiting
Brii Biosciences LimitedIndustry
NCT06650852 · 250 participants (planned) · Start Oct 31, 2024 · Primary completion Sep 2028
Drug: BRII-179; BRII-835 (VIR-2218) and 3 more · For: Chronic Hepatitis B Virus (HBV) Infection
Sites: Beijing, China; Guangzhou, China; Shenzhen, China · 14 sites in all
National Taiwan University HospitalAcademic, hospital or other
NCT04970836 · 240 participants (planned) · Start Aug 1, 2021 · Primary completion Dec 31, 2027
Drug: recombinant hepatitis B vaccine · For: Hepatitis B; Vaccination; Infection; Preventable Disease, Vaccine
Sites: Taipei, Taiwan
- "HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"Pivotal-lookingRecruiting
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT07054359 · 3,200 participants (planned) · Start Aug 10, 2026 · Primary completion Nov 10, 2028
Drug: Treatment by TDF if HBcrAg RDT positive; Treatment by TDF · For: HBV Infection; Pregnancy
Sites: Haiphong, Vietnam
The Second Affiliated Hospital of Chongqing Medical UniversityAcademic, hospital or other
NCT07852091 · 1,200 participants (planned) · Start Oct 10, 2023 · Primary completion Dec 31, 2026
Drug: Sintilimab/Envafolimab; ETV/TDF/TAF · For: Chronic Hepatitis B
Sites: Chongqing, China
- Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United StatesPivotal-lookingRecruiting
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT05832229 · 260 participants (planned) · Start Dec 7, 2023 · Primary completion Aug 31, 2029
Drug: Rosuvastatin · For: Cirrhosis; Cirrhosis, Liver; Cirrhosis Early and 5 more
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 13 sites in all
The Second Affiliated Hospital of Chongqing Medical UniversityAcademic, hospital or other
NCT07845058 · 1,200 participants (planned) · Start Oct 10, 2023 · Primary completion Dec 31, 2026
Drug: anti-PD-1/anti-PD-L1 antibody; NAs and 1 more · For: Chronic Hepatitis B; Anti-PD-1 Antibody; Anti-PD-L1 Antibody and 1 more
Sites: Chongqing, China
IntegerBioIndustry
NCT07389044 · 88 participants (planned) · Start Feb 20, 2026 · Primary completion Apr 30, 2027
Drug: IB-001; Peginterferon Alfa-2A · For: Chronic Hepatitis B Virus Infection
Sites: Hong Kong, Hong Kong; Chisinau, Moldova; Auckland, New Zealand · 5 sites in all
GigaGen, Inc.Industry
NCT07024641 · 48 participants (planned) · Start Nov 13, 2024 · Primary completion Nov 2028
Drug: GIGA-2339; Placebo · For: Hepatitis B Virus Infection
Sites: Chandler, Arizona; Huntington Beach, California; Lake Forest, California · 20 sites in all
The Second Affiliated Hospital of Chongqing Medical UniversityAcademic, hospital or other
NCT05769816 · 120 participants (planned) · Start Oct 10, 2023 · Primary completion Dec 31, 2026
Drug: Anti-PD-1 antibody; NAs · For: Chronic Hepatitis b; Anti-PD-1 Antibody
Sites: Chongqing, China
Bangladesh Medical UniversityAcademic, hospital or other
NCT07816094 · 48 participants (planned) · Start Jan 1, 2026 · Primary completion Jan 19, 2027
Drug: Entecavir · For: Hepatitis B
Sites: Dhaka, Bangladesh
The Second Affiliated Hospital of Chongqing Medical UniversityAcademic, hospital or other
NCT05771402 · 120 participants (planned) · Start Oct 10, 2023 · Primary completion Dec 31, 2026
Drug: Anti-PD-1 antibody; NAs and 1 more · For: Chronic Hepatitis b; Anti-PD-1 Antibody; Peg-IFNα
Sites: Chongqing, China
The Second Affiliated Hospital of Chongqing Medical UniversityAcademic, hospital or other
NCT07573943 · 120 participants (planned) · Start May 21, 2024 · Primary completion Dec 31, 2026
Drug: Anti-PD-L1 antibody (ASC22); Nucleotide analogs and 1 more · For: Chronic Hepatitis b
Sites: Chongqing, China
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07557251 · 21 participants (planned) · Start Aug 12, 2026 · Primary completion Dec 2028
Drug: BRII-5395; Sintilimab and 1 more · For: Advanced HBV-Related Hepatocellular Carcinoma
Sites: Beijing, China
- Study of LW231 in Participants With Chronic Hepatitis BPivotal-lookingRecruiting
Shanghai Longwood Biopharmaceuticals Co., Ltd.Industry
NCT07179575 · 270 participants (planned) · Start Nov 11, 2025 · Primary completion Mar 2027
Drug: LW231; LW231 placebo · For: Chronic HBV Infection
Sites: Hangzhou, China · 2 sites in all
Precision BioSciences, Inc.Industry
NCT06680232 · 45 participants (planned) · Start Nov 14, 2024 · Primary completion Dec 2026
Drug: PBGENE-HBV · For: HEPATITIS B CHRONIC
Sites: Boston, Massachusetts; Clichy, France; Hong Kong, Hong Kong · 7 sites in all
Fondazione Epatocentro TicinoAcademic, hospital or other
NCT06887036 · 10 participants (planned) · Start Sep 1, 2025 · Primary completion May 31, 2027
Drug: Methylene Blue · For: Chronic HBV Infection
Sites: Lugano, Switzerland
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.